Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 1,979 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total value of $157,053.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Darin Lippoldt also recently made the following trade(s):
- On Friday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $75.00, for a total value of $1,142,775.00.
- On Thursday, December 28th, Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $75.00, for a total value of $1,142,775.00.
- On Friday, December 8th, Darin Lippoldt sold 2,955 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $75.00, for a total value of $221,625.00.
- On Monday, December 4th, Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.04, for a total value of $471,176.16.
- On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $73.05, for a total value of $723,195.00.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded down $0.86 during trading on Thursday, reaching $79.00. The company had a trading volume of 746,749 shares, compared to its average volume of 1,130,194. The company has a market capitalization of $6,990.00, a price-to-earnings ratio of -35.59 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52 week low of $38.43 and a 52 week high of $83.84. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period in the previous year, the business earned ($0.43) earnings per share. sell-side analysts predict that Neurocrine Biosciences, Inc. will post -1.66 earnings per share for the current year.
Several equities research analysts recently weighed in on NBIX shares. BMO Capital Markets lifted their price target on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Jefferies Group restated a “buy” rating and set a $69.00 price target (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and a consensus target price of $81.13.
Several large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Crow Point Partners LLC purchased a new position in Neurocrine Biosciences during the 4th quarter worth $145,000. Stephens Inc. AR purchased a new position in Neurocrine Biosciences during the 2nd quarter worth $207,000. Comerica Bank purchased a new position in Neurocrine Biosciences during the 3rd quarter worth $210,000. Finally, Ardsley Advisory Partners purchased a new position in Neurocrine Biosciences during the 2nd quarter worth $230,000.
ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $157,053.44 in Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/neurocrine-biosciences-inc-nbix-insider-sells-157053-44-in-stock.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.